Chris Thom - CIM, DMS, FCSIAbbVie Inc.ABBVTRADEJul 31, 2025

They diversified from their hit drug, Humira, with new drug successfully. Margins are expanding and growing overall.

He just bought it. He's bullish pharma and biotech. They replaced Humana, their super drug, with others that are up 24%. He likes the 2.4% dividend and double-digit growth rate. He was waiting and can't wait anymore to enter this.

Has 7% earnings growth. New drugs have made up the lost revenue of Humera. It projects 24% revenue growth. He likes healthcare. Sees it breaking out.

Is up 6% the past month. She targets $232.

If it breaks above $219, she expects it to reach $234.

One of her holdings in the space. This higher-quality name has both growth and less execution risk.

Is up 15% the past year though flat this year. Still likes it. Their pipeline is cooking and other drugs are outpacing Humira.

Impressed how company has dealt with patent cliff on Humira. Has skillfully filled in blanks with new drugs and acquisitions. 

Is up 10% this year despite losing Humira. They have a strong drug pipeline, like Rinvoq up 40% YOY.

Abbvie and AZN are two good healthcare stocks, a sector in which you must be picky because of weakness. Both trade around 15x and pay around a 3% dividend yield.

Has owned this over a decade. Loves it when they bought Allergan. The concern lay with Humira coming off patent a year ago, but they used Humira's cash flow to diversify their entire franchise. Pays a solid yield and offers around 9% EPS growth.

It's up over 8% this year, beating the market. The PE is 15x. Has consistent topline growth due to Skyrizi as well as Botox and arthritis. High-quality. Pays a 3.5% dividend.

Has no patent cliff. They have great franchises in oncology, immunology and others. Shares are down because bond yields are rising. Dividend pays only 3.7%, below interest rates. That said, good to start a position now given their drugs, including Botox.